Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Gefitinib in Cervical Squamous Cell Carcinoma: CTRI/2026/06/112765 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/112765 clinical landscape for Cervical Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
BCMA-CAR-T cell-derived exosomes in BCMA Positive Multiple Myeloma: NCT07652138 Clinical Landscape Report 2026
16 September 2026
NCT07652138 clinical landscape for BCMA Positive Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in AIDS-Related Lymphoma: NCT07649304 Clinical Landscape Report 2026
16 September 2026
NCT07649304 clinical landscape for AIDS-Related Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant human thrombopoietin (Sunshine Pharmaceutical) in Thrombocytopenia: NCT07649395 Clinical Landscape Report 2026
16 September 2026
NCT07649395 clinical landscape for Thrombocytopenia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HBM-7020 in Sjogren's Syndrome: NCT07649265 Clinical Landscape Report 2026
16 September 2026
NCT07649265 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Uterine Cervical Cancer: NCT07653503 Clinical Landscape Report 2026
16 September 2026
NCT07653503 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Recurrent Endometrial Cancer: NCT07652515 Clinical Landscape Report 2026
16 September 2026
NCT07652515 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT07652242 Clinical Landscape Report 2026
16 September 2026
NCT07652242 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-5421 in Multiple Myeloma: NCT07652281 Clinical Landscape Report 2026
16 September 2026
NCT07652281 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Guselkumab in Arthritis, Psoriatic: NCT07654751 Clinical Landscape Report 2026
16 September 2026
NCT07654751 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NK Cell (Sinorda Bio) in Hepatocellular Carcinoma: NCT07657416 Clinical Landscape Report 2026
16 September 2026
NCT07657416 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Breast Cancer: CTRI/2026/06/113041 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/113041 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.